ESPR vs. RCUS, AVDL, AVXL, OCS, CMRX, CDMO, CRON, QURE, GHRS, and CRMD
Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Arcus Biosciences (RCUS), Avadel Pharmaceuticals (AVDL), Anavex Life Sciences (AVXL), Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), Cronos Group (CRON), uniQure (QURE), GH Research (GHRS), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.
Esperion Therapeutics vs. Its Competitors
Arcus Biosciences (NYSE:RCUS) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
In the previous week, Esperion Therapeutics had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 11 mentions for Esperion Therapeutics and 9 mentions for Arcus Biosciences. Esperion Therapeutics' average media sentiment score of 0.46 beat Arcus Biosciences' score of -0.12 indicating that Esperion Therapeutics is being referred to more favorably in the news media.
Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
Esperion Therapeutics has a net margin of -59.03% compared to Arcus Biosciences' net margin of -258.94%. Esperion Therapeutics' return on equity of -0.91% beat Arcus Biosciences' return on equity.
Arcus Biosciences presently has a consensus target price of $21.29, indicating a potential upside of 135.72%. Esperion Therapeutics has a consensus target price of $7.00, indicating a potential upside of 519.47%. Given Esperion Therapeutics' higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Arcus Biosciences.
Esperion Therapeutics has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.
92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Comparatively, 1.7% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Esperion Therapeutics beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks.
Get Esperion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Esperion Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ESPR) was last updated on 7/16/2025 by MarketBeat.com Staff
